(Paronychia)
1,969 results
  • CO2 Laser Matrixectomy for Refractory MEK Inhibitor-Induced Paronychia in Children: A Case Series. [Journal Article]
    Pediatr Blood Cancer. 2026 Jul 29; :e70466. [Online ahead of print]Friedland R, Noyman Y, … Toledano HPB
  • Paronychia is a frequent cutaneous adverse event associated with MEK inhibitor therapy and may significantly impair quality of life and compromise treatment adherence. Treatment is usually medical, with poor and unsustained results. We retrospectively evaluated the safety and efficacy of CO2 laser matrixectomy in children at a tertiary center between 2016 and 2026. Five patients with prolonged sy…
  • Hand Infections Across Tissue Planes: A Pictorial Review. [Review]
    Cureus. 2026 Jun; 18(6):e111341.Milovanovic U, Weimer DS, … Schwartz GC
  • Infections of the hand are encountered across emergency medicine, primary care, and surgical practice, and their outcomes depend heavily on early recognition. The complex anatomy of the hand, with its multiple fascial planes, tendon sheaths, and confined spaces, allows infection to spread rapidly and produce lasting functional impairment when treatment is delayed. This pictorial review presents a…
  • Drug-induced paronychia: a disproportionality and time-to-onset pharmacovigilance study using FAERS and JADER. [Journal Article]
    Cutan Ocul Toxicol. 2026 Jul 07; :1-12. [Online ahead of print]Xia J, Lu YCO
  • CONCLUSIONS: This pharmacovigilance assessment identified drugs with notable disproportionality signals for drug-induced paronychia, underscoring the utility of real-world data for early detection of safety signals. The identification of unlabeled paronychia risks in 32 medications highlights critical gaps in current safety information. These findings, derived from spontaneous reporting data, indicate associations rather than causal risk and require further clinical and epidemiologic evaluation. The signals identified may help prioritize pharmacovigilance monitoring and future validation studies.